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Abstract Genome editing of livestock is poised to
become commercial reality, yet questions remain as to
appropriate regulation, potential impact on the indus-
try sector and public acceptability of products. This
paper looks at how genome editing of livestock has
attempted to learn some of the lessons from commer-
cialisation of GM crops, and takes a systemic approach
to explore some of the complexity and ambiguity in
incorporating genome edited animals in a food
production system. Current applications of genome
editing are considered, viewed from the perspective of
past technological applications. The question of what
is genome editing, and can it be considered natural is
examined. The implications of regulation on develop-
ment of different sectors of livestock production
systems are studied, with a particular focus on the
veterinary sector. From an EU perspective, regulation
of genome edited animals, although not necessarily the
same as for GM crops, is advocated from a number of
different perspectives. This paper aims to open up new
avenues of research on genome edited animals,
extending from the current primary focus on science
and regulation, to engage with a wider-range of food
system actors.
Keywords Genome edited livestock  Regulation 
Production systems  Industry structure  Veterinarians
Introduction
Genome editing of livestock is advancing rapidly as a
technical field and may be poised to become com-
mercial reality. Yet questions remain as to appropriate
regulation, potential impact on the industry sector and
public acceptability of products. This paper examines
some of the complexity and ambiguity in incorporat-
ing genome edited animals into a food production
system. It takes as its starting point the commercial
introduction of genetically modified crops, and some
of the issues raised by early applications of genetic
modification to crops.
The commercial introduction of genetically mod-
ified (GM) crops in the early 1990s was initially fairly
uncontroversial. The widespread introduction in
maize, soya and oilseed rape, however, resulted in
social campaigns against GM crops in Europe and
elsewhere. Nevertheless, annual surveys from ISAAA
(2015) indicate widespread adoption of a limited
number of modified crops species (mostly oilseed
rape, soya and maize) and a limited number of traits
(mostly herbicide tolerance and insect resistance). The
research pipeline continues to offer novel crop appli-
cations (Parisi et al. 2016), although their penetration
into practical use has been slow to date. In contrast,
there are no genetically modified (GM) food animals
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being sold for food at the time of writing, to my
knowledge.
Several recent developments look set to change this
picture. The advent of genome editing techniques,
especially CRISPR-Cas9, is enabling changes to be
made at the DNA level, much more easily, precisely
and cheaply. The recent approvals of genetically
modified salmon for consumption both by the U.S.
Food and Drug Administration (2015), and Health
Canada (2016) provide evidence that it is possible for
GM products to satisfy regulatory requirements. In
addition, cheaper and faster DNA sequencing is
leading to increased understanding of the underlying
genetic basis of traits. Together these developments
potentially open up new opportunities for mar-
ketable genetic modification in food animal produc-
tion traits, hitherto unachievable.
Technological advances on their own are insuffi-
cient for market penetration, however. An entire
production system is involved, encompassing breed-
ers, producers, different markets, retailers and con-
sumers as well as regulators, animal welfare
advocates, veterinarians and other pertinent stake-
holders. And, most critically, products have to be
acceptable to publics. A livestock production system
thus consists of multiple stakeholders, each adapting
to shifting circumstances and opportunities in differ-
ent ways, but interacting with each other, and affecting
each other. These stakeholders each respond to
scientific developments, adjustments in markets,
changes in methods of production, and economic
and social pressures, in their own ways. The result is a
kaleidoscope of multiple complex interactions. This
paper explores some of this complexity and implica-
tions of adoption of genome edited livestock. It does
this in the context of early developments in GM crops
and their regulation.
This paper draws on long-term observation of
developments in genetics and livestock (e.g. Bruce
and Bruce 1998), including scientific developments,
regulatory changes, ethical and social challenges and
industry action. Evidence is based on publications
(including grey literature) and attendance at scientific,
regulatory and industry meetings, as well as formal
and informal conversations with individual stakehold-
ers in livestock production systems. Rapidly develop-
ing new technologies are offering novel possibilities
that could be attractive to the livestock production
sector, making an investigation of this subject timely.
This paper seeks to extend the recent focus of
publications on regulation of genome edited livestock
to a more systems-oriented approach, and suggests
that further investigation of interactions among the
stakeholders involved in livestock production is
therefore important.
This exploration of complexity starts with a review
of the current possible applications of genome editing
to livestock, based on publicly available data. It shows
how choices made by scientists regarding applications
to be developed have responded to criticisms of the
early developments in GM crops. Having established
what kind of genome edited products might be in the
pipeline, the next question considered is how these
developments relate to some of the key issues which
could affect their acceptance. These include argu-
ments around naturalness, transgenesis and regulation
that were raised by GM crops. Here I reflect on both
the similarities and differences between genetic mod-
ification and genome editing. Regulation will also
affect the relative competitiveness of different types of
companies; who might be the winners and who the
losers? The introduction of genome editing will
impact on other sectors of the livestock production
system. I will focus particularly on interactions with
veterinarians, given that many applications of genome
editing currently relate to disease resistance. Finally, I
reflect on the broader challenges to livestock produc-
tion and how genome editing relates to these chal-
lenges. The perspective will be European, and more
specifically from the UK.
Possibilities of genome edited animals
Animals produced by genome editing offer the
promise of precision modification to DNA, which
older methods also offered, but in some respects failed
to deliver. New precision engineering of the genome
(Fahrenkrug et al. 2010) is in contrast to the traditional
GM methods that largely relied on transfer of genes
between species (Clark and Whitelaw 2003). Early
enthusiasm at the prospects from GM animals (e.g.
Bulfield 1990) dissipated as producing commercial
GM animals proved to be more challenging than
seemed at first. A number of developments in molec-
ular biology have taken place over the last 15 year,
including gene manipulation, methods of introducing
genetic changes into animals, and understanding the
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underlying genetics (Bruce et al. 2013; Laible et al.
2015; Tan et al. 2016). In particular, the introduction
of genome editing tools have revitalised the research
area.
Genome editing involves the use of molecular
‘scissors’ to introduce changes into existing DNA, as
opposed to classical genetic modification which often
involved moving genes from one species to another.
Genome editing also enables a much wider-range of
changes, for example, gene knock-out, base pair
substitution, targeted insertion/deletion of larger
genomic regions, and modulation of gene expression
(e.g. Tan et al. 2016; Van Eenennaam 2017).
Social pressures to produce real benefits
In selecting which applications to focus on, many of
the developers of genome edited animals have sought
to learn from the controversies surrounding GM crops,
as well as welfare and ethical issues particular to
animals. Some early research applications of GM to
animals had also been subject to considerable scrutiny
regarding both animal welfare and the ethical accept-
ability of the procedures. Technology that was already
controversial in a crop context is perceived as even
more problematic when applied to sentient organisms,
such as farmed livestock (Coles et al. 2015). One of the
lessons taken by developers of genome edited animals
is that applications with an animal welfare benefit
would be expected to be much more acceptable to
publics than livestock with production advantages.
This is reflected in some of the early applications of
genome editing to livestock.
One of the early applications of genome editing is
to produce cows without horns (Recombinetics 2016).
Dairy cows with horns can harm each other and their
caretakers. Therefore it is common practice within the
industry to remove the horns from calves by chemical
or other means. This removal of horns is an unpleasant
procedure, which it would be beneficial to avoid.
Cows without horns (known as ‘polled’) exist natu-
rally, but they tend to be beef cattle with much poorer
milking ability. Using selective breeding to increase
the incidence of the polled gene variant (allele) in the
dairy herd would involve a very long process,
particularly if milk yield was maintained at the same
time. However, this gene variant has been introduced
into dairy cows directly using genome editing (Re-
combinetics 2016). The question remains whether
publics and animal welfare advocates perceive the
animal welfare benefit to be of sufficient magnitude to
justify such a biotechnological intervention. Whereas
people working directly with dairy cattle will be aware
of the processes involved in dehorning, and the
benefits of not having to do so, most publics are likely
to be unaware that dehorning processes take place,
let alone what these involve in practice. The advan-
tages of polled dairy cattle will not be immediately
obvious to those not versed in agricultural practice,
and the need for dehorning may be considered
shocking.
Increased disease resistance is another area that has
been addressed by genome editing, again with per-
ceived animal welfare benefits. Examples include pigs
tolerant to a fatal pig disease African Swine Fever
(Lillico et al. 2013) and pigs resistance to a serious
respiratory and reproductive disease, Porcine Repro-
ductive and Respiratory Syndrome (PRRS) (Whit-
worth et al. 2016). PRRS is an endemic pig disease in
numerous countries and has few treatment possibili-
ties. It negatively affects animal welfare and causes
large economic losses. African Swine Fever is a pig
disease endemic in Africa that causes up to 100%
mortality and for which effective treatments and
vaccines are not available. The disease has spread to
Russia, and most recently to Eastern Europe, where it
is seen as a threat toWestern European pig production.
Warthogs are found to be tolerant to African Swine
Fever and inspired a genome editing method which
has introduced the same tolerance alleles into domes-
ticated pigs in an experimental setting (Lillico et al.
2013).
The benefits of other applications of genome
editing may be perceived as more ambivalent.
Genome editing has been used to produce more
muscular animals in a variety of species, including
pigs, cattle and sheep, by introducing a change in the
myostatin gene (Cyranoski 2015; Proudfoot et al.
2015). The same change is naturally present in some
breeds of cattle. In the public mind, muscular appear-
ance often has connotations of poor welfare. Belgian
Blue cattle and Pietrain pigs are two breeds that are
muscular in appearance and of concern to animal
welfare advocates. Belgian Blue cattle have a high
incidence of problems when calving, and muscular
breeds of pigs have been associated with high
mortality rates. The causal mutation is in the myostatin
gene in Belgian Blue cattle and the ryanodine
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receptor/halothane gene in the Pietrain pig. The
question arises whether animal welfare advocates are
likely to be concerned by physical appearance, the
specific genetic change, both, or neither? The exper-
imental introduction reported by Proudfoot et al.
(2015) was in the context of very poorly muscled cattle
breeds, the resulting offspring physically appearing
normal rather than excessively muscled. The myo-
statin mutation also appears naturally in other breeds
such as Highland cattle, without apparent associated
welfare problems, so it may be possible to make the
case that editing the myostatin gene provides a benefit
in specific circumstances. However, the benefit is for
production rather than animal welfare. It is less easy to
see how a strong case can be made for more muscled
pigs if muscling in pigs is associated with poor welfare
(even when caused by a different genetic change).
Public perceptions associating muscled animals with
poor animal welfare can be difficult to shift and
applications resulting in increased muscling may
therefore prove to be controversial.
As is common with novel technologies, early
innovations frequently use material which is readily
available, such as already known gene variants. It
seems likely that increasingly innovative genome
edits will be developed. Suggestions in the scientific
literature include: producing offspring of a single
sex (e.g. for milk or egg production) (Fan et al.
2013; Tan et al. 2013), improved welfare by
avoiding castration (Tan et al. 2013), and the
prevention of the production of allergens and prion
proteins in animals (Yao et al. 2014; Ni et al. 2014).
Genome editing also has applications beyond the
production of food animals, notably for research for
understanding biological processes, in improved
models of human diseases and potentially for
production of animals for xenotransplantation. How-
ever, medical applications will not be considered
further in this paper.
Early applications of genome editing that come to
public attention are likely to shape how people think
about genome edited animals. These applications are
likely to influence what people think genome edited
animals are, and the purposes for which they have
been developed. The choices made amongst possible
applications of genome editing to animals are there-
fore important. Benefits perceived by scientific or
agricultural stakeholders, however, may be sometimes
difficult to convey to lay people.
Is genome editing natural?
An important feature of GM crops is that they are
viewed as unnatural by some people. The concept of
naturalness is complex, and cannot be considered in
detail in this article. However, as a recent report from
the UK Nuffield Council on Bioethics (2015) indi-
cates, naturalness should not be totally dismissed as an
argument because most people recognise the concept
as capturing something valid which should be taken
into account. The question remains as to whether any
breach of the natural order caused by genome editing
would constitute a moral hazard.
Since all genome edited applications rely on
laboratory intervention to develop parent animals, at
some level, all involve a degree of human artifice.
Bruce (2016), reflecting on whether genome editing is
‘unnatural’ or not from a moral reasoning perspective,
suggests that it is important to consider the nature of
the change brought about by genome editing. If
selective breeding (genetic selection) is considered
natural, and if the functional change brought about by
genome editing could have been achieved by selective
breeding, then it could be argued that there is little
reason to object to genome editing in principle. An
example is producing polled dairy cows. In this case,
the same DNA sequence exists in nature and in the
context of the same species. The question remains as
to why it would be seen as natural to undertake
selective breeding for a specific aim, but unnatural to
do the same in a laboratory using genome editing.
Genome editing may produce changes that are not
known to exist naturally in that species. But if these
could reasonably have occurred naturally, even if they
remained unrecognised by livestock breeders, it could
be argued that these changes are also ‘natural’. The
editing of resistance to PRRS into pigs might fit this
category, as it is a mutational knock-out of gene
function (Burkard et al. 2017).
It is easier to categorise as unnatural those appli-
cations where the resulting animal is unlikely to have
been achieved by normal mutation, for example
producing offspring of a single sex. It is therefore
possible to advance arguments that some genome
edited animals are more unnatural than others. There is
a similarity here with GM crops. It is possible to breed
crop plants resistant to specific herbicides using
traditional breeding methods, although the genetic
basis for the resistance may vary between GM crops
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and non-GM crops. Equally, it is possible to produce
novel applications by genetic modification, as exem-
plified both in GM crops and GM animals. It is
notable that the few current commercial applications
of genetic modification to animals involve the pro-
duction of pharmaceutical proteins (in milk or eggs).
These traits are unnatural, yet have utility to humans.
Clearly, just because something is considered unnat-
ural, does not necessarily mean it is undesirable.
Similarly, some natural mutations may be judged
undesirable.
Although philosophers, theologians, ethicists and
scientists may contest the various arguments as to
what constitutes naturalness, lay publics may conceive
of naturalness on a more intuitive basis. Such percep-
tion of unnaturalness can be very difficult to argue
against.
Is genome editing genetic modification?
The next lesson learned from experience with GM
crops is the controversial nature of moving genes
across species. An emphasis found in many scientific
papers is that genome editing does not necessarily
mean transgenic. Furthermore there is a tendency to
equate transgenic with genetically modified. An
example can be found in the report of genome editing
for resistance to PRRS (Whitworth et al. 2016) which
explicitly states that the resultant pigs are not trans-
genic and therefore not genetically modified. This
assertion is controversial, as the concept of what is
genetic modification varies both legally and, more
particularly, socially.
If the term ‘genetically modified’ is viewed as
synonymous with ‘transgenic’, the implication is that
since genome editing does not require the transfer of
DNA from one species to another, then genome edited
organisms, including livestock, are not genetically
modified. This semantic difference may be attractive
to proponents of genome edited animals, but it is
unlikely to convince everyone, given the technology
has developed in the context of genetic modification,
and can be viewed as evolving from those techniques.
The mere fact that genome editing comes from the
same ‘stable’ as genetic modification can be sufficient
to give it the same association.
On the other hand genome editing could also be
viewed as distinct from genetic modification. Genome
editing involves harnessing the cell’s natural repair
mechanisms to induce a specific change at a precise
location in the genome. This type of change could
have happened by natural mutation. Genome editing
could therefore be viewed as ‘induced mutation’, with
parallels to using radiation to induce mutations in
plants (although the latter is of course, random, and
would be unacceptable if applied to animals). How-
ever, genome editing is not perfectly controlled due to
‘off-site’ effects, although recent research suggest that
off-site effects can be controlled to a large extent (Tan
et al. 2016) and gene sequencing could be used to
detect presence or absence of off-site effects.
An alternative framing for genome editing could be
Marker Assisted Selection. Marker Assisted selection
relies on taking biological samples from animals and
analysing these for the presence or absence of genetic
markers associated with specific traits. Some of these
markers (such as the ryanodine receptor/halothane
gene) are single nucleotide changes. Marker Assisted
Selection has been viewed more favourably than
genetic modification by some stakeholder groups. For
example Greenpeace has advocated Marker Assisted
Selection in crop plants, on the basis of (1) respecting
species barriers; (2) increasing the efficiency of
traditional breeding without replacing it; and (3)
treating genomes as coherent entities rather than
transferring isolated gene sequences (Greenpeace
International 2009).
Genome editing has some similarities with Marker
Assisted Selection. It does not necessarily transgress
species barriers and arguably treats the genome as a
coherent entity in so far as any change involved is
mimicking a natural mutation. However, genome
editing does require a deliberate intervention that is
not possible without biotechnological capability that is
outside traditional farming practice. On the other
hand, ‘traditional’ farming practice has already been
supplemented in many cases by centralised specialist
procedures that lie outside the traditional farming
sphere. These include central performance testing,
semen distribution, data collection, sophisticated sta-
tistical analysis, and in the case of marker assisted
selection above, biological sampling and analysis.
Selective breeding is based on phenotypes, and
separation of genotype and environment using statis-
tical methods. This has further developed into
genomic selection, which involves the use of tens of
thousands of genetic markers across the genome rather
than relying on individual markers. Genomic selection
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has been made possible through increases in comput-
ing power, easier and cheaper availability of genotype
information, and developments in statistical tech-
niques. Genomic selection is being applied commer-
cially in, for example, dairy cattle. Since the physical
animal has already been ‘converted’ into data, and
these data are increasingly converted to genetic
information though genome selection, it seems a short
step to begin to manipulate these DNA changes in
purposeful ways. Genome editing and genome selec-
tion may even become integrated, as suggested by
Jenko et al. (2015). Thus the boundary between
current practice of genomic selection and genome
editing may become increasingly blurred.
What then is genome editing? Is it genetic modi-
fication? Induced mutation? Marker Assisted Selec-
tion? Or genome selection? Or something else? From
the above discussion, these definitions cannot be
answered merely from a scientific perspective,
because genetic modification has become as much a
social concept as a scientific concept.
The nuances that these descriptions capture for a
scientific audience can be difficult to understand for
those outside this specialist sphere. Evidence from
psychology suggests that when confronted by a new
phenomenon, people tend to use a fast way of thinking
in order to make sense of that phenomenon (e.g.
Forgas 2001; Kahneman 2011). This way of thinking
seeks to identify what the new phenomenon is similar
to, rather than carefully evaluating all the details. The
results of this type of thinking can seem illogical to
those versed in the details of a technology. In this way,
for example, for a lay audience, genome editing could
easily be rolled in with genetic modification, cloning
and tasteless tomatoes in supermarkets.
It would of course be advantageous for developers
of genome edited animals if they were able to avoid
the onerous regulations associated with genetic mod-
ification, so the argument that genome edited animals
are not genetically modified because they are not
transgenic, is attractive. In this next section I consider
the interactions between genome editing and
regulation.
GM regulation and genome editing
Two aspects of regulation are considered in this
section. The first is whether genome edited animals
should be subject to the same regulations as GM
animals. Here, I will primarily take an EU perspective,
given the variety of regulatory approaches around the
world. In this context, the main question is whether
genome editing counts as genetic modification and is
therefore subject to GM regulations? The second
reflection is on the impacts that GM crop regulation
has had on industry structures and the relative
competitiveness of different sectors.
GM regulation and genome editing
GM salmon (AquAdvantageTM) modified for faster
growth, has been at the forefront, worldwide, of the
regulatory process for GM animals for food produc-
tion (Van Eenennaam and Muir 2011). However, the
approval process for AquAdvantageTM salmon (which
used classical GM technology) was extremely oner-
ous, and supporters of genome edited animals advo-
cate much simpler, or even no regulatory constraints
for genome edited animals.
The EU regulatory system was developed in the
context of GM crops, is process based and depends on
a specific definition of genetic modification. The EU
defines a genetically modified organism as:
an organism, with the exception of human
beings, in which the genetic material has been
altered in a way that does not occur naturally by
mating and/or natural recombination (Directive
2001/18/EC, Article 2(2))
A key question is therefore whether genome editing
legally constitutes genetic modification in the EU or
not?While the EU continues to debate this issue, some
preliminary decisions have been made elsewhere.
A number of genome edited organisms have been
determined to fall outside the regulatory purview of
the USDA’s Animal and Plant Health Inspection
Service (APHIS) e.g. mushrooms edited using
CRISPR-Cas9 to reduce browning (Waltz 2016).
However, regulatory oversight in the USA is not
triggered by whether the process involves genetic
modification. Rather the regulatory triggers for GM
organisms are determined by the underlying laws and
regulatory authorities of each U.S. regulatory agency
and depends on the nature of the product. Similarly
genome edited crop plants, such as canola, have
gained Plant Novel Trait approval in Canada (Cibus
2014), where again regulation is not triggered by
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whether the process involves genetic modification.
Within the EU there continues to be debate as to the
regulatory status of plants produced by genome
editing, with a variety of different interpretations
being put forward (European Parliament 2016). The
Swedish Board of Agriculture has concluded that
some applications of CRISPR-Cas9 do not fall under
the EU definition of a Genetically Modified Organism
(GMO) and the German Federal Office for Consumer
Protection and Food Safety has come to a similar
conclusion (European Parliament 2016).
On January 18, 2017, the U.S. Food and Drug
Administration (2017) released for public comment
their Draft Guidance on the Regulation of Intention-
ally Altered Genomic DNA in Animals. The draft
guidance recommends that genome edited animals
should be regulated in a manner similar to that used by
the agency to regulate GM animals. At the time of
writing, the draft guidance was still in the public
comment period.
The narrow consideration of whether genome
editing is a form of genetic modification or not, does
not of course address the questions of what is the
purpose of regulation. From the perspective of differ-
ent genetic changes, Van Eenennaam and Young
(2015), cogently argue that current regulatory regimes
fail to reflect the scientific evaluation of risks from
different applications. In practice, however, objections
to developments may be on grounds other than risk,
but are nevertheless expressed in terms of risk, as the
only effective way of stopping a development that is
unwanted (Tait 2001). Examples of such objections
with respect to GM crops include excessive power of
commercial companies over food systems and exces-
sive industrialisation of agricultural practices. There is
no clear mechanism where such objections can be
considered, and hence arguments against develop-
ments tend to focus on risk.
In the context of GM crops, suggestions have been
made to establish ways of facilitating more open
debate around the non-science based evaluations
applied to policy decisions and making the basis for
policy decisions more explicit (Devos et al. 2013).
Areas suggested for more open debate by Devos et al.
include clarifying policy objectives, determining what
constitutes environmental (and by analogy animal
welfare) harm, making explicit the normative basis of
risk assessments (what level of risk is acceptable and
who should bear the risk), and weighing harms against
benefits.
If genome editing is to be harnessed for animal
welfare, environmental or social benefit then some
kind of regulatory or other ‘carrot’ to drive in these
directions, would provide the greatest opportunity
for such developments, rather than merely relying on
markets. An example from another industry sector, is
the U.S. Food Quality Protection Act that gives
preference to pesticides which provide environmen-
tal benefits over current products. Some jurisdictions
in Europe already include requirements for social
benefit in the context of regulatory approval of
biotechnology-derived animals. For example, Nor-
way requires GMOs to benefit society and be
ethically justifiable as well as not harmful (Library
of Congress 2014). In Denmark cloning and genetic
modification of animals is restricted to applications
benefitting human health and the environment
(NordForsk 2016). In the Netherlands, genetic mod-
ification of animals for food purposes needs a license
requiring the product to serve a public interest and
have no overriding ethical objections (Government
of the Netherlands 2016). However, these are all
examples of regulatory ‘sticks’, designed to prevent
applications, rather than ‘carrots’ designed to pro-
mote applications considered to be particularly
beneficial.
Regulatory regimes for genome edited livestock
remain unclear, however, attempting to avoid all
regulation could stimulate accusations that genome
editing is trying to avoid public debate. By hiding the
nature of genome editing developments people may be
prevented from having any choice in the matter. Even
if the regulatory regime for GM organisms is judged
excessive for genome edited organisms, some kind of
opportunity for public debate, and provision of
methods for identifying products from genome edited
animals seems necessary. For example, setting stan-
dards for genome edited animals, perhaps drawing on
the experiences of regulation of medical devices.
Given that producing genome edited animals will
require serious investment, it is likely that developers
will seek to recoup costs by selling the resulting
breeding animals at a premium, and therefore will not
seek to ‘hide’ the fact that the animal is a result of




Interaction between regulation and company
strategies
Turning now to the second aspect of regulation, that of
interactions between regulation, company strategies,
relative competitiveness and innovation trajectories.
Regulation arguable impacts are not just on the safety
and efficacy of innovations but also on company
strategies and the types of firm likely to be successful
(Mittra et al.2011). Tait (2007) suggests that adopting
a high regulatory burden for GM crops meant that
large, multinational agrochemical companies were
favoured over traditional crop seed producing firms.
The agrochemical companies had both the funds and
the expertise to deal with complex regulatory require-
ments, which the seed companies did not have. If
genome edited livestock will be required to comply
with the same regulatory standards as GM crops, then
again companies with the resources to cope with such
regulatory burdens are likely to be favoured.
Analysis of agrochemical company strategies (Tait
2007; Tait and Chataway 2007) suggested that genetic
modification of crops was disruptive innovation for
this industry sector. Agrochemical companies used to
innovation based on small chemical molecules needed
novel innovation pathways for producing GM crops.
The companies could not continue using existing
innovation pathways, but instead required path-break-
ing innovation involving new areas of research and
new markets. At early stages of development of GM
crops, agrochemical companies used various strate-
gies to deal with this disruptive innovation, including
acquiring seed companies (Monsanto and Dupont),
collaborating with seed companies (AgrEvo, Zeneca,
Novartis, Rhine Poulenc and Dow) or waiting to
observe developments (BASF and Bayer) (Mittra et al.
2011).
In comparison, GM crops would have been incre-
mental innovation for traditional seed producing
companies. They could have continued their current
innovation trajectories and gained competitive advan-
tage through existing business practices (Tait 2007).
Tait (2007) further suggests that had seed companies
produced GM crops, the public outcome for GM crops
may have been very different. The high standard of
evidence required to satisfy regulatory requirements,
however, has meant that regulation has effectively
acted as a barrier to entry for smaller traditional seed
producing firms (Tait 2007).
Research papers reporting the achievement of a few
genome edited animals are important accounts of
scientific advancements. However, it is not enough
just to produce three or four genome edited animals for
the application to become commercially viable. To
produce a commercially viable product, the number of
animals needs to be increased, and the animals and
their products accepted by a range of stakeholders,
including animal breeders, farmers, vets and super-
market chains, as well as successfully negotiate any
regulatory barriers. A plausible route to market is
needed. In the case of genome edited animals, current
developments appear to include those where a plau-
sible route to market is developing. For example a
major, global livestock breeding company, Genus plc,
has announced it has an exclusive licence to use
genome editing to commercially produce pigs resis-
tant to PRRS (Genus 2015).
The international livestock breeding sector is well
organised, particularly when considering chickens,
pigs and dairy cows, although with some heterogene-
ity. A number of global breeding companies dominate
the sector. Specialist breeding companies undertake
genetic selection to produce the next generation of
livestock, multiply this stock (and often produce cross
breeds) and sell to commercial farmers. Unlike crops,
where the whole population can be rapidly replaced,
introducing genome editing into a livestock popula-
tion is a much more complex and time consuming
process.
Although the entry of one major breeding company
into genome editing is noted, the breeding company
model is not the only one in existence in the supply of
breeding stock, as state intervention in livestock
breeding has been common in many European coun-
tries. As with other industry sectors, there is evidence
that the breeding sector has been shaped in part by
regulation. In France, for example, state intervention,
and then the withdrawal of the state from the breeding
sector has had a profound impact on the commercial
stakeholders (Hannachi and Tichit 2016). The 1966
Livestock Act, introduced to encourage the use of
Artificial Insemination, resulted in the creation of
monopoly breeder co-operatives in different regions,
and the loss of influence by key individual breeders.
The later Agricultural Orientation Law (2006) resulted
in loss of state intervention, which together with
technological changes due to the introduction of
genomic selection, allowed the entry of multinational
Transgenic Res
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companies into the breeding sector. Hannachi and
Tichit argue the result is that cattle breeding in France
has moved from being a collective, collaborative
exercise, to one that is practiced individually and
characterised by competition (Hannachi and Tichit
2016). This is an example from the livestock produc-
tion sector of the influence that regulation can play on
subsequent industry development.
The nature of the genome editing application may
also have an impact on the innovation trajectory and
its impact on different parts of the livestock production
system. Applications such as polledness are likely to
be path-dependent for farms, although suppliers of
materials to dehorn animals may see their markets
decline andmay need to identify novel markets. A cow
which does not develop horns is still just a cow and the
basic farm business model is not disrupted by its lack
of horns. The hornlessness reflects improved animal
welfare, labour savings in avoiding an unpleasant task
and economic savings in materials and labour. How-
ever, other potential genome edited products have the
potential for more disruptive impacts.
The ability to avoid the need for castrating animals
could have stronger animal welfare benefits, and
additional benefits in reduced labour requirements, as
well as better performance from animals that do not
suffer a growth-check from the procedure. The process
may also be potentially disruptive, for example if this
allows novel meat products to be developed as pigs
could be slaughtered at heavier weights if the taste
taint from males is absent. An application which
provides the ability of only producing commercially
useful animals of the desirable sex has the potential to
be disruptive in ways which are hard to predict, as
reproduction could be limited to specific farms. There
may need to be novel social or institutional arrange-
ments that allow maintenance of the parent animals of
both sexes, with consequent impacts on costs of
production and distribution of control and ownership
of breeding stock.
Public acceptability of such radical applications
also need to be questioned. Few such data exist
currently, although for example an on-line survey in
the Netherlands (Gremmen and Blok 2016) asked
respondents to compare the acceptability of a number
of different options for dealing with unwanted male
chicks in egg production. The respondents in this
survey considered that genetically modifying chickens
so that eggs with male chicks could be identified by
green fluorescence, was more acceptable than taking
biological samples from non-genetically modified
eggs to identify males by laboratory means. Although
this is a small example, and may not be reflected in
broader acceptability of using genome editing to alter
sex ratios, it does indicate the importance of examin-
ing public attitudes rather than presuming them.
Within the livestock production systems, different
stakeholders are likely to be affected in different ways.
Genome edited animals are sold to farmers not
consumers. For farmers, genome edited animals are
likely to be incremental innovations, whose manage-
ment is path dependent. The ‘product’ is after all, a
cow or pig, like any other. There may be additional
recording and identification requirements if labelling
and co-existence requirements are similar to those for
GM crops in the EU. However, the demands for
recording individual animals and animal movements
in the EU are already considerable.
For breeders without laboratory science expertise,
developing genome edited animals is likely to be path
breaking, requiring the acquisition of new skills.
However, larger companies in this sector have a very
high degree of technical absorptive capacity. Distri-
bution of genome edited animals is likely to be path
dependent as the methods of distribution depend on
the physical material. However, meeting the require-
ments of intellectual property regimes allied to
genome edited animals may prove to be disruptive.
Hitherto the intellectual property in livestock breeding
has been primarily protected by secrecy and use of
cross-breeding. Genome edited animals could be path-
dependent for meat processors and retailers, unless
there are consumer requirements for labelling or
campaigns against such products, in which case
genome edited animals could require new business
practices to be developed. One sector that could easily
be affected, and for whom this is potentially a path-
breaking development, is the veterinary sector.
Veterinary sector
Disease control is an initial focus for several genome
editing projects, the examples of African Swine Fever
and PRRS were given above. These diseases have few
or no alternative treatments and also pose a significant
economic threat to pig production. If genome edited
disease resistant or tolerant animals are to be widely
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adopted, disease resistance would need to be incorpo-
rated into overall disease management strategies at the
individual farm, or even national, level.
Genetic disease resistance is intended to be used in
disease prevention. However, based on a historical
analysis of UK veterinary practice, Woods (2013)
argues that vets have used the rhetoric of disease
prevention, but found it difficult to deliver in practice
for a variety of reasons. They have instead maintained
an approach that focusses on treatments. Woods
suggests that for effective prevention, an appropriate
combination of veterinary, disease, farming and
political drivers are required, all of which promote
disease prevention. An important step is to engage the
veterinary profession and other appropriate stakehold-
ers to identify the drivers necessary for genome edited
animals to be harnessed for animal health improve-
ment. Some reflections on issues worth exploring are
given in the following paragraphs.
Genome edited animals are unlikely to be adopted
by all farmers. Therefore, it is likely that disease
resistant or tolerant (depending on the nature of the
edit), and disease susceptible animals would co-exist
in commercial populations. Understanding the epi-
demiological implications (if any) of introducing a
novel resistance trait to some animals, could be one of
the questions being addressed. Such an examination
could also uncover veterinarians’ perceptions of
genome edited disease resistant animals and the
potential impact of such animals on their work.
Veterinarians are responsible for implementing
disease control measures, particularly where there
are specific legal requirements for doing so. This
would be the case should there be a suspected
emergence of African Swine Fever in the UK, for
example. Genome editing thus could have much wider
implications, because the suspicion that a notifiable
disease of international significance is present can
cause major disruption to international trade. The
potential implications of genome editing for disease
resistance in the event of any future outbreak of such
diseases could therefore be explored by a range of
stakeholders.
Part of the current European policy landscape is
that the costs of exotic disease prevention should be
shared between government and farmers, as opposed
to governments bearing all the costs of exotic disease
prevention. Could farmers be encouraged to keep
disease resistant livestock by being given a greater
compensation if they do so, if an exotic disease
outbreak were to occur? Farmer behaviour related to
livestock disease is complex and context specific
(Barnes et al. 2015). But if farmers were to be offered
higher compensation for adopting disease resistant
animals, then the resistance would need to be attested
to in some way. This suggests the need for some kind
of standards certification, which would identify ani-
mals with appropriate disease resistance
characteristics.
While these considerations are not unique to
genome edited animals—some of the same could
apply to selective breeding for disease resistance—
addressing these types of questions could be important
when considering commercial realities of genome
edited animals. Taking account of the way in which
veterinarians’ practices interact with genome edited
animals in different circumstances would test interac-
tions among different parts of a livestock production
system.
The future of livestock production
GM crops were introduced in the late 1990s at a time
when the use of chemicals in agriculture had become
controversial. Advocating the introduction of crops
that promoted the use of a pesticide or herbicide
(although environmentally more benign than some
others) in this context provided a ready basis for public
resistance. There are currently many different (and
often competing) visions for the future of livestock
agriculture that set the wider context for genome
editing. For example, the sector has come under
intense pressure from environmental considerations,
particularly the need to reduce greenhouse gas emis-
sions, while at the same time responding to the
imperative to increase livestock production to feed
burgeoning populations (Godfrey et al. 2010). A
recent policy paper from a European livestock indus-
try perspective starts from the premise that the
livestock sector has been identified as the world’s
largest user of natural resources (Knowledge for
Innovation 2015). This policy paper calls for innova-
tion in the livestock sector that is environmentally
sound, socially responsible and economically viable.
The extent to which genome edited animals can
contribute to visions of the future of agriculture will
impact on future trajectories. Many different future
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visions exist. Two contrasting visions are provided
here, as exemplars.
One vision of the future of agriculture focusses on
the current, conventional, global systems of livestock
production as typifying such a future. Typically, farms
would continue to provide livestock products for
global markets, with a strong emphasis on the
efficiency of production. This vision would be likely
to embrace application of various technologies such as
exploiting information technology and the use of rapid
environmental and biological diagnostics. Within this
vision, measures to improve efficiency would be
valued and might encompass a range of metrics, such
as carbon footprints, the efficiency of use of animal
feed for growth, and biological measures such as
reproductive efficiency. Contributing to these effi-
ciency measures would be viewed as contributing to
delivering environmentally sound, socially responsi-
ble and economically viable livestock production. In
such a context, genome edited animals could be seen
as consistent with these aspirations.
In contrast to the global production system, there
are a group of alternative livestock production systems
which aspire to transform the global production
system. These alternative production systems are
diverse, and include for example, Community Sup-
ported Agriculture, urban agriculture, local produc-
tion, andmarketing through farmers’ markets and food
hubs. They have developed partly as a way of resisting
what is perceived as the dysfunctional current global
production system. A key criticism of the global
system is the way in which consumers have become
separated from producers. Rather than emphasise
metrics of efficiency, these alternative production
systems stress equitable relationships between con-
sumers and producers, and between livestock and
human beings. Traditional forms of knowledge and
use of breeds adapted to local conditions are empha-
sised. New knowledge is by no means rejected but the
role that genome edited animals could play in such a
scenario is more questionable.
Genome editing for improved adaption to local
conditions might be compatible with the aims of
‘alternative’ systems, for example if animals were
edited to be more heat tolerant. However, genome
editing may be rejected in principle by advocates of
this future vision, on the grounds of reflecting an
excessively instrumental relationship between humans
and livestock. The emphasis in this future vision on
resistance to global livestock production systems may
also militate against genome editing, if genome
editing is perceived to be associated with those global
systems.
Conclusions: key lessons for genome edited
livestock
Genome editing promises the possibility of producing
commercial livestock carrying precise genetic
changes, which are difficult or impossible to achieve
with selective breeding. Ultimately, the future of these
developments will depend on political decisions,
regulatory requirements and public acceptability, as
well as technological capabilities. This paper has
sought to draw on the experiences of the introduction
of GM crops to examine the development of genome
edited livestock. In particular, this paper extends the
focus on science and regulation, to considering the
wider context of livestock production systems.
Early applications of genome editing to livestock
have taken into account the need to provide publicly
recognised benefits, as a lesson learned from the
production-focus of early GM crops applications.
Initial applications have mainly focussed on welfare
and disease resistance traits, although more profound
changes to animal physiology have also been sug-
gested, and may be realised in future. One of the
challenges of meeting public aspirations for welfare
benefit is the difficulty of agreeing on what is a welfare
benefit. What may seem beneficial, or at least neutral,
in terms of animal welfare for those familiar with
livestock production, can be more controversial for
others. Public views on more profound changes to
physiology, e.g. altering sex ratios, are as yet, largely
unexamined. In general attitudes are likely to be
influenced by the particular reason given for the
application, how beneficial or risky it is considered to
be, and specific context of application and the
alternatives available.
Early applications of genome editing in livestock
have also focused on creating gene variants that exist
in the same, or similar species, and seeking to avoid
crossing species boundaries. Given the tendency
among some people to conflate genetic modification
with transgenesis, genome editing might be thought to
provide an opportunity to avoid the regulatory impasse
that in many cases has been a feature of GM animals.
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However, avoiding regulation for genome edited
animals on the basis that they do not involve crossing
species barriers would restrict applications of genome
editing only to those that meet this requirement, and
could discourage many other developments. At the
other extreme, avoiding any kind of regulation for
genome edited animals could also easily result in a
public back-lash. Some publics may see unregulated
adoption of the technology as a way to introduce (by
stealth) practices that they think are cruel or unnec-
essary. A carefully nuanced mechanism for identify-
ing and regulating genome edited animals seems
essential.
Genome editing applied to livestock production is
not just a technical fix that can be effortlessly adopted
without consequences to the wider production system.
Stakeholders in the wider industry may react in ways
that perturb current practices. These perturbations can
be application specific or context specific, and may be
difficult to predict without engagement with a range of
appropriate stakeholders. In the case of GM crops,
regulatory requirements and company strategies led to
multinational agrochemical companies being
favoured over crop seed producers. Early indications
for genome edited livestock are, that at least one global
breeding company is willing to adopt genome editing
and has the capacity to deliver genome edited
livestock to farmers. Adoption of genome editing is
consistent with the expertise present in this company.
It is not clear what impact genome editing will have on
other industry stakeholders, such as smaller breeding
organisations or nationally supported breeding co-
operatives.
Genome edited specific disease resistant livestock
can have implications on management of disease, in
particular diseases that are exotic to the particular
jurisdiction and which have the potential to disrupt
international trade. On the other hand, disease resistant
livestock could be incorporated as part of a package of
actions aimed at better prevention of disease.
The wider context of livestock production is also
important to consider. Pressure is increasing on the
sector to reduce its environmental impact, while
maintaining productivity. Whether genome editing
can contribute to these aspirations remains to be seen.
Public support for genome edited livestock is
essential for the promised products to gain wide
market penetration. Frivolous, or controversial appli-
cations raising public disquiet have the potential to
make it very difficult for future genome edited
livestock applications to be socially accepted. Com-
petition to be the first on the market needs to be
tempered by consideration of the wider future of the
technology. Focussing on technology and its regula-
tory implications is important but more attention needs
to be paid to interactions among stakeholders to better
understand how genome edited animals could impact
the broader livestock production sector.
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